Trastuzumab Biosimilar

About Hansoh Pharma

Hansoh Pharmaceutical Group is one of China's premier pharmaceutical companies, specializing in innovative drug development across oncology, central nervous system disorders, and other therapeutic areas. Founded in 1995, the company has successfully commercialized multiple products in China and is expanding its pipeline with novel small molecules and biologics. Hansoh went public on the Hong Kong Stock Exchange in 2019 and continues to invest heavily in R&D to develop first-in-class and best-in-class therapies.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is a vertically integrated pharmaceutical company with capabilities spanning drug discovery, development, manufacturing, and commercialization. The company has built a strong portfolio of generic drugs, particularly in the US market, while also investing in complex generics, biosimilars, and proprietary drug development. With manufacturing facilities across multiple countries and a global workforce, Dr. Reddy's continues to expand its market presence through strategic partnerships, acquisitions, and new product launches. The company is publicly traded on both Indian stock exchanges and NASDAQ, reflecting its status as a major player in the global pharmaceutical industry.

About Strides Pharma

Strides Pharma is a global pharmaceutical company headquartered in Bengaluru, India, with a core mission to provide affordable, high-quality generic medicines worldwide. The company has established itself as a leader in niche and complex therapeutic segments, including anti-retrovirals, anti-malarials, and softgel technologies, with a significant footprint in the US, Africa, Asia, and other regulated markets. Its strategic direction involves expanding its portfolio of complex generics, biosimilars, and specialty products while leveraging its robust manufacturing and R&D capabilities. Key achievements include a successful IPO, strategic acquisitions, and a consistent track record of ANDA filings and approvals in the US market.

Therapeutic Areas

Other HER2+ Breast Cancer Drugs